Business
Stem Cell Therapy
Organoid
Stem Cell and CDMO Business
R&D
Core Technology
The first advanced bio-convergence combination product for osteoarthritis
OSCA is an advanced bio-convergence therapeutic product for the treatment of osteoarthritis, composed of human umbilical cord blood–derived mesenchymal stem cells and porcine cartilage–derived acellular cartilage matrix.
Mechanism of action of OSCA for the treatment of osteoarthritis
Following intra-articular administration, CAM Inj., enhances the secretion of active factors from the stem cell, thereby triggering cartilage and subchondral bone regeneration, protection of intra-articular tissues, and anti-inflammatory effects.
Human umbilical cord blood–derived mesenchymal stem cells, a well-established therapeutic cell source for osteoarthritis treatment
Chondrogenic
differentiation potential
NOD2
expression levels
FURESTEM-OA Inj. is a stem cell product that has been confirmed to exhibit superior chondrogenic differentiation potential and higher expression levels of immunomodulatory factors compared with stem cells derived from other tissue sources.
A high-functionality ECM-based injectable formulation similar to native cartilage matrix
CAM Inj. uses porcine cartilage–derived acellular extracellular matrix as its primary material and is composed of components highly similar to those of native cartilage matrix.
Amplification of stem cell efficacy by CAM Inj.
![Amplification of stem cell efficacy by CAM Inj.]](/imgs/business/en/furestemOA05.png)
Stem cells treated with CAM Inj. exhibit increased TGF-β1 secretion, thereby enhancing signaling pathways that promote chondrocyte differentiation. In addition, a microenvironment conducive to cartilage tissue formation is established.
Verification of cartilage regeneration efficacy through large animal studies (goat)
In a goat model of osteoarthritis, administration of OSCA resulted in a regenerative trend in damaged cartilage, suggesting that intra-articularly administered OSCA has the potential to promote cartilage repair.
Verification of joint function recovery through large animal studies (goat)
ACLT (OA)
+ OSCA
In gait (lameness) assessments in a goat osteoarthritis model, the OSCA-treated group showed a more favorable trend in joint function recovery, which was maintained for up to 12 months.